

# Andreas Seeber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1691285/publications.pdf>

Version: 2024-02-01

63  
papers

949  
citations

567281

15  
h-index

501196

28  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1587  
citing authors

#	ARTICLE	IF	CITATIONS
1	FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?. <i>Life</i> , 2022, 12, 81.	2.4	15
2	Molecular profile of hepatocellular carcinoma (HCC) in older versus younger adults: Does age matter?. <i>Journal of Clinical Oncology</i> , 2022, 40, 477-477.	1.6	0
3	High SARS-CoV-2 vaccination coverage but still room for improvement in patients with haemophilia: A single-centre analysis. <i>Haemophilia</i> , 2022, 28, .	2.1	1
4	Comprehensive Analysis of R-Spondin Fusions and <i>RNF43</i> Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1863-1870.	7.0	16
5	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. <i>Oncogene</i> , 2022, 41, 3455-3460.	5.9	19
6	Age as a factor in the molecular landscape and the tumor-microenvironmental signature of osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11525-11525.	1.6	1
7	The tumor microenvironment and immune infiltration landscape of <i>KRAS</i> mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4142-4142.	1.6	2
8	Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8515-8515.	1.6	1
9	CXCR4 overexpression: An indicator of poor survival and predictor of response to immunotherapy in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3546-3546.	1.6	2
10	Differential expression of somatostatin receptor (SSTR) subtypes across a spectrum of neuroendocrine neoplasms (NENs).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3071-3071.	1.6	1
11	The prognostic significance of <i>TP53</i> mutations in patients with right-sided and left-sided colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3589-3589.	1.6	0
12	Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4018-4018.	1.6	2
13	Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. <i>Cancers</i> , 2022, 14, 3332.	3.7	11
14	Olaratumab plus anthracycline in advanced/metastatic soft tissue sarcoma. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 21-25.	1.9	3
15	High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 304-313.	2.8	23
16	Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	3.2	1
17	High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4021-4021.	1.6	6
18	Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11555-11555.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Peritoneal or mesenteric tumours revealing histiocytosis. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000622.	2.7	3
20	The Emerging Role of Liquid Biopsy in Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2108.	2.4	20
21	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021, 40, 4894-4905.	5.9	19
22	Rare lung cancers – Primary pulmonary leiomyosarcoma: A case report. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 392-396.	0.5	1
23	Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition. <i>Lung Cancer</i> , 2021, 159, 84-95.	2.0	12
24	Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072199368.	2.5	0
25	Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 662055.	2.8	12
26	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	5.4	9
27	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. <i>Translational Lung Cancer Research</i> , 2021, 10, 4477-4493.	2.8	14
28	The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies. <i>Translational Lung Cancer Research</i> , 2021, 10, 4600-4616.	2.8	5
29	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020, 140, 119-129.	2.8	37
30	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	4.1	14
31	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000942.	4.5	26
32	Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives. <i>Cancers</i> , 2020, 12, 2001.	3.7	2
33	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020, 26, 5943-5951.	7.0	55
34	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	3.7	10
35	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	4.5	64
36	Diagnostic and therapeutic management of sarcoma patients. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 141-142.	0.5	0

#	ARTICLE	IF	CITATIONS
37	The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. <i>Journal of Clinical Medicine</i> , 2020, 9, 1005.	2.4	3
38	Disseminated focal 18F-fluoro-deoxyglucose uptake upon granulocyte colony-stimulating factor therapy mimicking malignant bone infiltration: case report of a patient with very severe aplastic anemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072097761.	2.5	2
39	Resistance in gastrointestinal stromal tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 140-143.	0.5	2
40	Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 23.	1.5	5
41	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3096-3103.	7.0	65
42	Curcumin: New Insights into an Ancient Ingredient against Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1808.	4.1	109
43	Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 447-453.	4.1	17
44	Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 73-79.	2.0	5
45	Molecular landscape of colorectal cancers harboring R-spondin fusions.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3588-3588.	1.6	7
46	Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 606-606.	1.6	5
47	High IDO expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. <i>Cancer Science</i> , 2018, 109, 1583-1591.	3.9	53
48	Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition. <i>Stem Cells Translational Medicine</i> , 2018, 7, 495-501.	3.3	59
49	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2087.	4.1	14
50	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12106-12106.	1.6	2
51	Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3572-3572.	1.6	6
52	Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3577-3577.	1.6	0
53	Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3611-3611.	1.6	0
54	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4098-4098.	1.6	0

#	ARTICLE	IF	CITATIONS
55	What's new in small cell lung cancer â€“ extensive disease? An overview on advances of systemic treatment in 2016. <i>Future Oncology</i> , 2017, 13, 1427-1435.	2.4	4
56	The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 255-258.	0.5	0
57	Reply. <i>Clinical Lung Cancer</i> , 2016, 17, e187.	2.6	1
58	Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. <i>European Journal of Cancer</i> , 2016, 67, 91-98.	2.8	17
59	Incidental Diagnosis of Asymptomatic Nonâ€“Small-Cell Lung Cancer: A Registry-Based Analysis. <i>Clinical Lung Cancer</i> , 2016, 17, 62-67.e1.	2.6	18
60	Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. <i>Genes and Cancer</i> , 2016, 7, 301-308.	1.9	15
61	Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. <i>Lung Cancer</i> , 2015, 87, 193-200.	2.0	115
62	Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. <i>Oncotarget</i> , 2015, 6, 25017-25023.	1.8	14
63	Detection of soluble EpCAM in malignant ascites to predict overall survival in patients treated with catumaxomab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15173-e15173.	1.6	0